Literature DB >> 8202446

Effects on intestinal microflora, gastrointestinal tolerability and antiinflammatory efficacy of diclofenac and nitrofenac in adjuvant arthritic rats.

L Cuzzolin1, A Conforti, M Donini, A Adami, P Del Soldato, G Benoni.   

Abstract

Since it is known that nitric oxide plays an important protective role in maintaining the tissue integrity and is cytotoxic for invasive micro-organisms, diclofenac and a new original diclofenac-derivate, nitrofenac (containing the nitric oxide group), was administered at doses of 0.3 and 3 mg kg-1 per os to adjuvant arthritic rats. At the 14th, 21st and 28th days after arthritis induction, the antiinflammatory efficacy and the effects on intestinal microflora of the two drugs were evaluated; moreover, at the end of the study period, the gastrointestinal tract was examined macroscopically for any presence of lesions. Daily oral administration of diclofenac and nitrofenac at 3 mg kg-1 markedly and significantly inhibited arthritis development until the end of the study period. Some significant changes were observed in anaerobic and Gram-negative bacterial flora, particularly the total disappearance, in all treated rats, of Escherichia coli 1, also 7 days after the last drug administration. Finally, no ulcers or severe damage were observed macroscopically with either drug, even if some alterations in the mucosa and haemorrhagic effusions were more evident in rats treated with diclofenac at 3 mg kg-1. In conclusion, in this chronic model a similar therapeutic efficacy of diclofenac and nitrofenac is shown in arthritic rats. The better gastrointestinal tolerability observed in nitrofenac-treated rats could be attributed to the release of nitric oxide.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8202446     DOI: 10.1016/1043-6618(94)80101-0

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  5 in total

1.  Role of endogenous and exogenous nitric oxide on intestinal mucosa and microflora in the rat.

Authors:  L Cuzzolin; A Adami; F Crivellente; G Benoni
Journal:  Inflammation       Date:  1997-08       Impact factor: 4.092

2.  Variability of oral bioavailability for low dose methotrexate in rats.

Authors:  T Kuroda; K Namba; T Torimaru; S Yamamoto; M Akahori
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2001 Oct-Dec       Impact factor: 2.441

Review 3.  Pharmacology and potential therapeutic applications of nitric oxide-releasing non-steroidal anti-inflammatory and related nitric oxide-donating drugs.

Authors:  J E Keeble; P K Moore
Journal:  Br J Pharmacol       Date:  2002-10       Impact factor: 8.739

4.  Cytoprotection and healing: two unequal brethren.

Authors:  F Halter; B Peskar; K D Rainsford; A Schmassmann
Journal:  Inflammopharmacology       Date:  1997       Impact factor: 4.473

5.  The gastrointestinal microbiome and musculoskeletal diseases: a beneficial role for probiotics and prebiotics.

Authors:  Luis Vitetta; Samantha Coulson; Anthony W Linnane; Henry Butt
Journal:  Pathogens       Date:  2013-11-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.